{"id":"NCT03672175","sponsor":"Biogen","briefTitle":"A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder","officialTitle":"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-19","primaryCompletion":"2019-09-24","completion":"2020-03-17","firstPosted":"2018-09-14","resultsPosted":"2022-11-10","lastUpdate":"2023-11-29"},"enrollment":581,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"SAGE-217","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SAGE-217 Matched Placebo","type":"PLACEBO_COMPARATOR"},{"label":"SAGE-217 20 mg","type":"EXPERIMENTAL"},{"label":"SAGE-217 30 mg","type":"EXPERIMENTAL"}],"summary":"This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).","primaryOutcome":{"measure":"Change From Baseline in the 17-item HAM-D Total Score at Day 15","timeFrame":"Baseline (BL), Day 15","effectByArm":[{"arm":"SAGE-217 Matched Placebo","deltaMin":-11.1,"sd":0.59},{"arm":"SAGE-217 20 mg","deltaMin":-11.5,"sd":0.62},{"arm":"SAGE-217 30 mg","deltaMin":-12.5,"sd":0.68}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6638"},{"comp":"OG000 vs OG002","p":"0.1158"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":53,"countries":["United States"]},"refs":{"pmids":["36811520"],"seeAlso":["http://www.sagerx.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":190},"commonTop":["Headache","Diarrhoea","Dizziness","Somnolence","Sedation"]}}